<DOC>
	<DOC>NCT00238797</DOC>
	<brief_summary>The purpose of the study is to determine the efficacy of gefitinib (IressaTM) in combination with radiotherapy on patients with glioblastoma multiforme.</brief_summary>
	<brief_title>A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Signed informed consent histologicallyor cytologicallyconfirmed glioblastoma multiforme age 18 years or older Have had prior radiation therapy, immunotherapy, gene therapy and/or chemotherapy for the glioblastoma coexisting malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ known severe hypersensitivity to ZD1839 or any of the excipients of this product.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>Brain tumour</keyword>
</DOC>